JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Aktien・NeoGenomics Inc

NeoGenomics Inc

Geschlossen

8.99 -4.87

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.99

Max

9.65

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -9.9M
Verkäufe	2.4M 190M
Gewinnspanne	-5.196
Angestellte	2,500
EBITDA	15M 5.3M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+58.26% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	28. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-352M 1.1B
Vorheriger Eröffnungskurs	13.86
Vorheriger Schlusskurs	8.99

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

7.7 / 10.27 Unterstützung & Widerstand

NeoGenomics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

NeoGenomics Inc Prognose

Kursziel

By TipRanks

58.26% Vorteil

12-Monats-Prognose

Durchschnitt 14.94 USD 58.26%

Hoch 25 USD

Tief 11 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für NeoGenomics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für NeoGenomics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

7.7 / 10.27Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.